Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen

Kevin M. McKown, Laura D Carbone, Juan Bustillo, Jerome M. Seyer, Andrew H. Kang, Arnold E. Postlethwaite

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective. To determine whether oral tolerance to type I collagen (CI) could be induced in patients with systemic sclerosis (SSc). Methods. Twenty adult patients with limited or diffuse SSc were enrolled in a study to receive 0.1 mg of solubilized native bovine CI daily for 1 month, followed by 0.5 mg daily for 11 months. Peripheral blood mononuclear cells (PBMC) were obtained from the patients and cultured with human α1(I) and α2(I) chains, before and after CI treatment. Culture supernatants were analyzed for levels of interferon-γ (IFNγ) and interleukin-10 (IL-10). Sera obtained before and after treatment were analyzed for levels of soluble IL-2 receptor (sIL-2R). Although this study was not intended to assess the clinical efficacy of oral CI administration in SSc, selected measures of disease severity and organ involvement were evaluated. Results. Oral administration of CI to SSc patients induced significant reductions in levels of IFNγ and IL-10 in α1(I)- and α2(I)-stimulated PBMC culture supernatants, indicating that T cell immunity to CI was decreased by this treatment. Serum levels of sIL-2R also decreased significantly after oral CI treatment, suggesting a reduction in T cell activation. Significant improvements occurred in the modified Rodnan skin thickness score and the modified Health Assessment Questionnaire after 12 months of oral CI in this open trial. The lung carbon monoxide diffusing capacity improved statistically and showed a trend toward clinically significant improvement. Conclusion. Oral administration of bovine CI to patients with diffuse or limited SSc induces a reduction in T cell reactivity to human CI, appears to be well tolerated, and does not worsen the disease. Further evaluation of oral tolerance to CI in patients with SSc is justified to determine whether it has therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)1054-1061
Number of pages8
JournalArthritis and Rheumatism
Volume43
Issue number5
DOIs
StatePublished - May 1 2000

Fingerprint

Immune Tolerance
Systemic Scleroderma
Collagen Type I
Oral Administration
Interleukin-2 Receptors
T-Lymphocytes
Interleukin-10
Interferons
Blood Cells
Therapeutics
Diffuse Scleroderma
Carbon Monoxide
Serum
Immunity
Cell Culture Techniques
Lung
Skin
Health

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. / McKown, Kevin M.; Carbone, Laura D; Bustillo, Juan; Seyer, Jerome M.; Kang, Andrew H.; Postlethwaite, Arnold E.

In: Arthritis and Rheumatism, Vol. 43, No. 5, 01.05.2000, p. 1054-1061.

Research output: Contribution to journalArticle

McKown, Kevin M. ; Carbone, Laura D ; Bustillo, Juan ; Seyer, Jerome M. ; Kang, Andrew H. ; Postlethwaite, Arnold E. / Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. In: Arthritis and Rheumatism. 2000 ; Vol. 43, No. 5. pp. 1054-1061.
@article{ab518e1b5baa4154b1914c88d642e977,
title = "Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen",
abstract = "Objective. To determine whether oral tolerance to type I collagen (CI) could be induced in patients with systemic sclerosis (SSc). Methods. Twenty adult patients with limited or diffuse SSc were enrolled in a study to receive 0.1 mg of solubilized native bovine CI daily for 1 month, followed by 0.5 mg daily for 11 months. Peripheral blood mononuclear cells (PBMC) were obtained from the patients and cultured with human α1(I) and α2(I) chains, before and after CI treatment. Culture supernatants were analyzed for levels of interferon-γ (IFNγ) and interleukin-10 (IL-10). Sera obtained before and after treatment were analyzed for levels of soluble IL-2 receptor (sIL-2R). Although this study was not intended to assess the clinical efficacy of oral CI administration in SSc, selected measures of disease severity and organ involvement were evaluated. Results. Oral administration of CI to SSc patients induced significant reductions in levels of IFNγ and IL-10 in α1(I)- and α2(I)-stimulated PBMC culture supernatants, indicating that T cell immunity to CI was decreased by this treatment. Serum levels of sIL-2R also decreased significantly after oral CI treatment, suggesting a reduction in T cell activation. Significant improvements occurred in the modified Rodnan skin thickness score and the modified Health Assessment Questionnaire after 12 months of oral CI in this open trial. The lung carbon monoxide diffusing capacity improved statistically and showed a trend toward clinically significant improvement. Conclusion. Oral administration of bovine CI to patients with diffuse or limited SSc induces a reduction in T cell reactivity to human CI, appears to be well tolerated, and does not worsen the disease. Further evaluation of oral tolerance to CI in patients with SSc is justified to determine whether it has therapeutic efficacy.",
author = "McKown, {Kevin M.} and Carbone, {Laura D} and Juan Bustillo and Seyer, {Jerome M.} and Kang, {Andrew H.} and Postlethwaite, {Arnold E.}",
year = "2000",
month = "5",
day = "1",
doi = "10.1002/1529-0131(200005)43:5<1054::AID-ANR14>3.0.CO;2-W",
language = "English (US)",
volume = "43",
pages = "1054--1061",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen

AU - McKown, Kevin M.

AU - Carbone, Laura D

AU - Bustillo, Juan

AU - Seyer, Jerome M.

AU - Kang, Andrew H.

AU - Postlethwaite, Arnold E.

PY - 2000/5/1

Y1 - 2000/5/1

N2 - Objective. To determine whether oral tolerance to type I collagen (CI) could be induced in patients with systemic sclerosis (SSc). Methods. Twenty adult patients with limited or diffuse SSc were enrolled in a study to receive 0.1 mg of solubilized native bovine CI daily for 1 month, followed by 0.5 mg daily for 11 months. Peripheral blood mononuclear cells (PBMC) were obtained from the patients and cultured with human α1(I) and α2(I) chains, before and after CI treatment. Culture supernatants were analyzed for levels of interferon-γ (IFNγ) and interleukin-10 (IL-10). Sera obtained before and after treatment were analyzed for levels of soluble IL-2 receptor (sIL-2R). Although this study was not intended to assess the clinical efficacy of oral CI administration in SSc, selected measures of disease severity and organ involvement were evaluated. Results. Oral administration of CI to SSc patients induced significant reductions in levels of IFNγ and IL-10 in α1(I)- and α2(I)-stimulated PBMC culture supernatants, indicating that T cell immunity to CI was decreased by this treatment. Serum levels of sIL-2R also decreased significantly after oral CI treatment, suggesting a reduction in T cell activation. Significant improvements occurred in the modified Rodnan skin thickness score and the modified Health Assessment Questionnaire after 12 months of oral CI in this open trial. The lung carbon monoxide diffusing capacity improved statistically and showed a trend toward clinically significant improvement. Conclusion. Oral administration of bovine CI to patients with diffuse or limited SSc induces a reduction in T cell reactivity to human CI, appears to be well tolerated, and does not worsen the disease. Further evaluation of oral tolerance to CI in patients with SSc is justified to determine whether it has therapeutic efficacy.

AB - Objective. To determine whether oral tolerance to type I collagen (CI) could be induced in patients with systemic sclerosis (SSc). Methods. Twenty adult patients with limited or diffuse SSc were enrolled in a study to receive 0.1 mg of solubilized native bovine CI daily for 1 month, followed by 0.5 mg daily for 11 months. Peripheral blood mononuclear cells (PBMC) were obtained from the patients and cultured with human α1(I) and α2(I) chains, before and after CI treatment. Culture supernatants were analyzed for levels of interferon-γ (IFNγ) and interleukin-10 (IL-10). Sera obtained before and after treatment were analyzed for levels of soluble IL-2 receptor (sIL-2R). Although this study was not intended to assess the clinical efficacy of oral CI administration in SSc, selected measures of disease severity and organ involvement were evaluated. Results. Oral administration of CI to SSc patients induced significant reductions in levels of IFNγ and IL-10 in α1(I)- and α2(I)-stimulated PBMC culture supernatants, indicating that T cell immunity to CI was decreased by this treatment. Serum levels of sIL-2R also decreased significantly after oral CI treatment, suggesting a reduction in T cell activation. Significant improvements occurred in the modified Rodnan skin thickness score and the modified Health Assessment Questionnaire after 12 months of oral CI in this open trial. The lung carbon monoxide diffusing capacity improved statistically and showed a trend toward clinically significant improvement. Conclusion. Oral administration of bovine CI to patients with diffuse or limited SSc induces a reduction in T cell reactivity to human CI, appears to be well tolerated, and does not worsen the disease. Further evaluation of oral tolerance to CI in patients with SSc is justified to determine whether it has therapeutic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0034121227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034121227&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(200005)43:5<1054::AID-ANR14>3.0.CO;2-W

DO - 10.1002/1529-0131(200005)43:5<1054::AID-ANR14>3.0.CO;2-W

M3 - Article

C2 - 10817559

AN - SCOPUS:0034121227

VL - 43

SP - 1054

EP - 1061

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -